Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‑kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
S. E. Coutre
Honoraria - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
J. C. Byrd
Consultant or Advisory Role - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
R. R. Furman
Honoraria - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
J. R. Brown
Honoraria - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
D. M. Benson
Research Funding - Calistoga Pharmaceuticals
N. D. Wagner-Johnston
Research Funding - Calistoga Pharmaceuticals
I. W. Flinn
Honoraria - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
B. S. Kahl
Honoraria - Calistoga Pharmaceuticals
Research Funding - Calistoga Pharmaceuticals
S. E. F. Spurgeon
Research Funding - Calistoga Pharmaceuticals
B. J. Lannutti
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
H. K. W. Hsu
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
R. Ulrich
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
S. Peterman
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
L. Holes
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
L. L. Miller
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
A. S. Yu
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals